Molecular Assessment for Endometrial Carcinoma
Percentage of pathology reports for endometrial carcinoma that comment on POLE and p53 testing status, and status of IHC for PMS2 and MSH6.
Percentage of pathology reports for endometrial carcinoma that comment on POLE and p53 testing status, and status of IHC for PMS2 and MSH6.